Matinas BioPharma Holdings, Inc.
MTNBDrugs in Pipeline
5
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Omega 3 pentaenoic acid
Hypertriglyceridemia
Drug Omega 3
Hypertriglyceridemia
Amphotericin B
Candidiasis, Chronic Mucocutaneous
MAT2203
Cryptococcal Meningitis
Oral Encochleated Amphotericin B (CAMB)
Vulvovaginitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Omega 3 pentaenoic acid | Phase 2 | Hypertriglyceridemia | - | - |
Drug Omega 3 | Phase 2 | Hypertriglyceridemia | - | - |
Amphotericin B | Phase 2 | Candidiasis, Chronic Mucocutaneous | - | - |
MAT2203 | Phase 2 | Cryptococcal Meningitis | - | - |
Oral Encochleated Amphotericin B (CAMB) | Phase 2 | Vulvovaginitis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Matinas BioPharma Holdings, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Matinas BioPharma Holdings, Inc.'s (MTNB) pipeline across Phase 2. Its lead program is Omega 3 pentaenoic acid (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Matinas BioPharma Holdings, Inc.'s next FDA catalyst?→
Matinas BioPharma Holdings, Inc.'s (MTNB) next tracked catalyst is a Earnings expected November 9, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MTNB biotech catalysts?→
Add MTNB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Matinas BioPharma Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.